• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于德语版PRO-CTCAE的患者报告结局工具的语言和内容验证,用于评估异基因造血干细胞移植后的迟发效应症状体验。

Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.

作者信息

Kirsch Monika, Mitchell Sandra A, Dobbels Fabienne, Stussi Georg, Basch Ethan, Halter Jorg P, De Geest Sabina

机构信息

Institute of Nursing Science, University of Basel, Switzerland; Department of Haematology, University Hospital Basel, Switzerland.

Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, United States.

出版信息

Eur J Oncol Nurs. 2015 Feb;19(1):66-74. doi: 10.1016/j.ejon.2014.07.007. Epub 2014 Sep 1.

DOI:10.1016/j.ejon.2014.07.007
PMID:25190633
Abstract

PURPOSE

The aim of this sequential mixed methods study was to develop a PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)-based measure of the symptom experience of late effects in German speaking long-term survivors of allogeneic stem cell transplantation (SCT), and to examine its content validity.

METHODS

The US National Cancer Institute's PRO-CTAE item library was translated into German and linguistically validated. PRO-CTCAE symptoms prevalent in ≥50% of survivors (n = 15) and recognized in its importance by SCT experts (n = 9) were identified. Additional concepts relevant to the symptom experience and its consequences were elicited. Content validity of the PROVIVO (Patient-Reported Outcomes of long-term survivors after allogeneic SCT) instrument was assessed through an additional round of cognitive debriefing in 15 patients, and item and scale content validity indices by 9 experts.

RESULTS

PROVIVO is comprised of a total of 49 items capturing the experience of physical, emotional and cognitive symptoms. To improve the instrument's utility for clinical decision-making, questions soliciting limitations in activities of daily living, frequent infections, and overall well-being were added. Cognitive debriefings demonstrated that items were well understood and relevant to the SCT survivor experience. Scale Content Validity Index (CVI) (0.94) and item CVI (median = 1; range 0.75-1) were very high.

CONCLUSIONS

Qualitative and quantitative data provide preliminary evidence supporting the content validity of PROVIVO and identify a PRO-CTCAE item bundle for use in SCT survivors. A study to evaluate the measurement properties of PROVIVO and to examine its capacity to improve survivorship care planning is underway.

摘要

目的

这项序贯混合方法研究的目的是开发一种基于PRO-CTCAE(不良事件通用术语标准的患者报告结局)的测量方法,用于评估德语区异基因造血干细胞移植(SCT)长期存活者的迟发效应症状体验,并检验其内容效度。

方法

将美国国立癌症研究所的PRO-CTAE项目库翻译成德语并进行语言验证。确定了在≥50%的存活者(n = 15)中普遍存在且被SCT专家(n = 9)认为重要的PRO-CTCAE症状。引出了与症状体验及其后果相关的其他概念。通过对15名患者进行新一轮的认知反馈,以及9名专家对项目和量表内容效度指数的评估,来评估PROVIVO(异基因SCT后长期存活者的患者报告结局)工具的内容效度。

结果

PROVIVO总共包含49个项目,涵盖身体、情感和认知症状的体验。为提高该工具在临床决策中的实用性,增加了询问日常生活活动受限、频繁感染和总体健康状况的问题。认知反馈表明,这些项目易于理解且与SCT存活者的经历相关。量表内容效度指数(CVI)(0.94)和项目CVI(中位数 = 1;范围0.75 - 1)非常高。

结论

定性和定量数据提供了初步证据,支持PROVIVO的内容效度,并确定了用于SCT存活者的PRO-CTCAE项目集。一项评估PROVIVO测量特性并检验其改善生存护理计划能力的研究正在进行中。

相似文献

1
Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.一种基于德语版PRO-CTCAE的患者报告结局工具的语言和内容验证,用于评估异基因造血干细胞移植后的迟发效应症状体验。
Eur J Oncol Nurs. 2015 Feb;19(1):66-74. doi: 10.1016/j.ejon.2014.07.007. Epub 2014 Sep 1.
2
Perception of late effects among long-term survivors after haematopoietic stem cell transplantation: Descriptive analysis and validation of the Brief Illness Perception Questionnaire. A sub-study of the PROVIVO study.造血干细胞移植后长期存活者对远期效应的认知:简明疾病认知问卷的描述性分析与验证。PROVIVO研究的一项子研究。
Eur J Oncol Nurs. 2017 Apr;27:17-27. doi: 10.1016/j.ejon.2017.01.003. Epub 2017 Feb 9.
3
Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国立癌症研究所不良事件通用术语标准患者报告结局版(PRO-CTCAE)的丹麦语翻译及语言验证
J Pain Symptom Manage. 2016 Aug;52(2):292-7. doi: 10.1016/j.jpainsymman.2016.02.008. Epub 2016 Apr 15.
4
Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.美国国立癌症研究所不良事件通用术语标准患者报告结局韩文版的语言验证
J Glob Oncol. 2019 Mar;5:1-10. doi: 10.1200/JGO.18.00193.
5
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).患者报告结局常用术语标准不良事件(PRO-CTCAE®)意大利语版的文化适应性调整。
Tumori. 2023 Jun;109(3):324-334. doi: 10.1177/03008916221099558. Epub 2022 Jun 8.
6
Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).德国患者报告的不良事件通用术语标准(PRO-CTCAE™)版本的验证。
Ann Oncol. 2016 Dec;27(12):2294-2299. doi: 10.1093/annonc/mdw422. Epub 2016 Sep 28.
7
Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国立癌症研究所不良事件通用术语标准患者报告结局(PRO-CTCAE)西班牙语版本的语言验证。
Support Care Cancer. 2016 Jul;24(7):2843-51. doi: 10.1007/s00520-015-3062-5. Epub 2016 Feb 2.
8
Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).美国国立癌症研究所不良事件通用术语标准患者报告结局版(PRO-CTCAE™)的荷兰语翻译及语言验证。
J Patient Rep Outcomes. 2020 Oct 6;4(1):81. doi: 10.1186/s41687-020-00249-y.
9
Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.美国国家癌症研究所患者报告结局通用术语标准不良事件的韩语版的可靠性和有效性。
J Pain Symptom Manage. 2020 May;59(5):1082-1088.e6. doi: 10.1016/j.jpainsymman.2020.01.015. Epub 2020 Feb 8.
10
Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE™)简体中文版的语言验证。
BMC Cancer. 2020 Nov 26;20(1):1153. doi: 10.1186/s12885-020-07631-5.

引用本文的文献

1
Health information management of older, multimorbid patients in German primary care: feasibility and first results of the outcome measures of a cluster-randomised controlled pilot trial - HYPERION-TransCare.德国初级保健中多病共存老年患者的健康信息管理:一项整群随机对照试验——HYPERION-TransCare的可行性及结局指标的初步结果
BMC Prim Care. 2025 Apr 5;26(1):98. doi: 10.1186/s12875-025-02774-5.
2
Medication Risks and Their Association with Patient-Reported Outcomes in Inpatients with Cancer.癌症住院患者的用药风险及其与患者报告结局的关联
Cancers (Basel). 2024 May 31;16(11):2110. doi: 10.3390/cancers16112110.
3
Implementation and evaluation of a complex intervention to improve information availability at the interface between inpatient and outpatient care in older patients with multimorbidity and polypharmacy (HYPERION-TransCare) - study protocol for a pilot and feasibility cluster-randomized controlled trial in general practice in Germany.
实施与评估一项复杂干预措施,以提高患有多种疾病和多种药物治疗的老年患者住院与门诊护理衔接处的信息可得性(HYPERION-TransCare)——德国全科医疗中一项试点及可行性整群随机对照试验的研究方案
Pilot Feasibility Stud. 2023 Aug 22;9(1):146. doi: 10.1186/s40814-023-01375-2.
4
Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.开发针对肿瘤的 PRO-CTCAE 项目集:在三家德国门诊癌症中心的横断面调查分析。
BMC Cancer. 2023 Jul 5;23(1):629. doi: 10.1186/s12885-023-11115-7.
5
Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).《儿童患者报告结局版常见不良事件术语标准(PRO-CTCAE)》的斯瓦希里语翻译与文化调适。
J Patient Rep Outcomes. 2023 Jun 12;7(1):56. doi: 10.1186/s41687-023-00598-4.
6
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).患者报告结局常用术语标准不良事件(PRO-CTCAE®)意大利语版的文化适应性调整。
Tumori. 2023 Jun;109(3):324-334. doi: 10.1177/03008916221099558. Epub 2022 Jun 8.
7
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.建立全国性靶向口服抗癌药物治疗药物监测基础设施:ON-TARGET研究方案。
Cancers (Basel). 2021 Dec 14;13(24):6281. doi: 10.3390/cancers13246281.
8
Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth-the SMILe study.基于电子健康(eHealth)的异基因干细胞移植综合护理模式的开发——SMILe 研究。
Support Care Cancer. 2021 Dec;29(12):8045-8057. doi: 10.1007/s00520-021-06328-0. Epub 2021 Jul 5.
9
Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE™)简体中文版的语言验证。
BMC Cancer. 2020 Nov 26;20(1):1153. doi: 10.1186/s12885-020-07631-5.
10
Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).美国国立癌症研究所不良事件通用术语标准患者报告结局版(PRO-CTCAE™)的荷兰语翻译及语言验证。
J Patient Rep Outcomes. 2020 Oct 6;4(1):81. doi: 10.1186/s41687-020-00249-y.